Synapse - Sergio Giralt

Results (349)

The hematopoietic cell transplant-co-morbidity index (HCT-CI) predicts outcomes after T cell depleted (TCD) allogeneic HCT for AML and MDS

Meeting Abstract

Ratan, R.; Ceberio, I.; Hilden, P.; Devlin, S. M.; Malloy, M. A.; Barker, J. N.; Castro-Malaspina, H.; Jakubowski, A. A.; Koehne, G.; Papadopoulos, E. B.; more...
Blood (2013)

Fulltext@MSK | Save

High day 28 ST2 biomarker levels predict severe day 100 acute graft-versus-host disease and day 180 transplant-related mortality after double-unit cord blood transplantation

Meeting Abstract

Ponce, D. M.; Hilden, P.; Mumaw, C.; Devlin, S.; Lubin, M. N.; Evans, K. L.; Prockop, S.; Scaradavou, A.; Kernan, N. A.; Giralt, S. A.; more...
Blood (2013)

Fulltext@MSK | Save

Multiple copies of MLL is the most commonly detected cytogenetic abnormality in newly diagnosed multiple myeloma and may modify disease risk

Meeting Abstract

Landry, C.; Londono, D.; Devlin, S. M.; Lesokhin, A.; Lendvai, N.; Hassoun, H.; Chung, D. J.; Koehne, G.; Jhanwar, S. C.; Giralt, S. A.; more...
Blood (2013)

Fulltext@MSK | Save

Pilot study to evaluate the prevalence of actionable oncogenic mutations in patients with relapsed refractory multiple myeloma

Meeting Abstract

Lesokhin, A.; Gonen, M.; Redling, K.; Lendvai, N.; Hassoun, H.; Landau, H.; Chung, D. J.; Koehne, G.; Patel, M.; Brennan, K. W.; more...
Blood (2013)

Fulltext@MSK | Save

T-cell depleted allogeneic hematopoietic stem cell transplantation for patients with relapsed multiple myeloma and high-risk cytogenetics permits long-lasting remissions in the absence of graft-versus-host disease

Meeting Abstract

Koehne, G.; Devlin, S. M.; Landau, H.; Hassoun, H.; Lesokhin, A.; Lendvai, N.; Chung, D. J.; Bravo, C.; Giralt, S.
Blood (2013)

Fulltext@MSK | Save

Two chemotherapy-based conditioning regimens compared to TBI-based conditioning secure consistent engraftment of T-cell depleted allogeneic HSCT, similarly low incidences of GVHD and favorable rates of disease-free survival (DFS)

Meeting Abstract

Koehne, G.; Boulad, F.; Klein, E. G.; Barker, J. N.; Castro-Malaspina, H. R.; Curran, K. J.; Giralt, S. A.; Goldberg, J. D.; Hasan, A. N.; Heller, G.; more...
Blood (2013)

Fulltext@MSK | Save

Outcomes in patients with acute lymphoblastic leukemia in first or second complete remission receiving ex-vivo T-cell depleted or unmodified allografts: Comparison of results at two institutions

Meeting Abstract

Hobbs, G. S.; Hilden, P.; Hamdi, A.; Goldberg, J. D.; Poon, M.; Ledesma, C.; Devlin, S.; Rondon, G.; Papadopoulos, E. B.; Jakubowski, A. A.; more...
Blood (2013)

Fulltext@MSK | Save

Prospective evaluation of alternative donor availability in 708 patients: Improved allograft access with enlarging CB inventory for all patients including racial and ethnic minorities

Meeting Abstract

Dahi, P. B.; Ponce, D. M.; Byam, C.; Devlin, S.; Lubin, M. N.; Evans, K. L.; Gonzales, A. M. R.; Sideroff, M.; Wells, D.; Giralt, S. A.; more...
Blood (2013)

Fulltext@MSK | Save

Phase 1 trial of carfilzomib + high dose melphalan conditioning regimen prior to autologous hematopoietic stem cell transplantation (AHSCT) for relapsed multiple myeloma

Meeting Abstract

Costa, L. J.; Landau, H.; Venkata, J. K.; Kang, Y.; Koehne, G.; Chung, D. J.; Lendvai, N.; Bentz, T.; Giralt, S.
Blood (2013)

Fulltext@MSK | Save

T-cell depleted (TCD) hematopoietic stem cell transplantation (HCT) for adult patients with acute myelogenous leukemia (AML) In first and second remission: Long-term disease free survival (DFS) with a significantly reduced risk of graft-versus-host disease (GvHD)

Meeting Abstract

Ceberio, I.; Hilden, P.; Devlin, S. M.; Maloy, M.; Goldberg, J. D.; Perales, M. A.; Barker, J. N.; Castro-Malaspina, H.; Koehne, G.; Ponce, D. M.; more...
Blood (2013)

Fulltext@MSK | Save

Sergio Andres Giralt

Results (349)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract